Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Replimune Group, Inc. before investing.

In this article, we go over a few key elements for understanding Replimune Group, Inc.’s stock price such as:

• Replimune Group, Inc.’s current stock price and volume
• Why Replimune Group, Inc.’s stock price changed recently
• Upgrades and downgrades for REPL from analysts
• REPL’s stock price momentum as measured by its relative strength

About Replimune Group, Inc. (REPL)

Before we jump into Replimune Group, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Want to learn more about Replimune Group, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Replimune Group, Inc..

Replimune Group, Inc.’s Stock Price as of Market Close

As of May 23, 2025, 12:31 PM, CST, Replimune Group, Inc.’s stock price was $8.410.

Replimune Group, Inc. is down 4% from its previous closing price of $8.760.

During the last market session, Replimune Group, Inc.’s stock traded between $7.805 and $8.740. Currently, there are approximately 77.01 million shares outstanding for Replimune Group, Inc..

Replimune Group, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Replimune Group, Inc. Stock Price History

Replimune Group, Inc.’s (REPL) price is currently down 14.01% so far this month.

During the month of May, Replimune Group, Inc.’s stock price has reached a high of $10.300 and a low of $6.840.

Over the last year, Replimune Group, Inc. has hit prices as high as $17.000 and as low as $4.920. Year to date, Replimune Group, Inc.’s stock is down 30.55%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Replimune Group, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of May 22, 2025,, no analysts have changed their rating of Replimune Group, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Replimune Group, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Replimune Group, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Replimune Group, Inc. (REPL) by visiting AAII Stock Evaluator.

Relative Price Strength of Replimune Group, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 22, 2025, Replimune Group, Inc. has a weighted four-quarter relative price strength of 6.14%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how Replimune Group, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Replimune Group, Inc. Stock Price: Bottom Line

As of May 23, 2025, Replimune Group, Inc.’s stock price is $8.410, which is down 4% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Replimune Group, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.